Cytek Biosciences, Inc. revenue
Cytek Biosciences, Inc.'s revenue was $201m in fiscal 2025, up 0.5% on the year before. Since fiscal 2020 ($92.8m) it has grown at a compound 16.8% a year. Over the last twelve months it was $207m.
Revenue history
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 93 | 128 | 164 | 193 | 200 | 201 | 207 |
| Growth on the year before | — | +37.8% | +28.2% | +17.7% | +3.9% | +0.5% | — |
| Gross profit | 52 | 79 | 101 | 109 | 111 | 104 | 110 |
| Gross margin | 55.7% | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% | 53.2% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $144M | 71.6% | ▼ 5.9% |
| Services | $57.3M | 28.4% | ▲ 21.3% |
| Region | Revenue | YoY |
|---|---|---|
| United States | $95.3M | ▲ 2.9% |
| EMEA | $55.9M | ▼ 10.4% |
| Asia Pacific | $41.1M | ▲ 14.8% |
| China | $20.5M | — |
| Other | $9.3M | ▼ 4.6% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Cytek Biosciences, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Cytek Biosciences, Inc. | $207m | 5.4% | 5.6% |
| Maravai Lifesciences Holdings, Inc. | $209m | -5.0% | -27.3% |
| Cryoport, Inc. | $186m | 12.1% | -8.2% |
| Mesa Laboratories Inc | $250m | 3.0% | 4.4% |
| Grail, Inc. | $165m | 23.1% | — |
| Schrodinger, Inc. | $259m | 8.9% | 10.2% |
Compare with peers
- Maravai Lifesciences Holdings, Inc. revenue
- Cryoport, Inc. revenue
- Mesa Laboratories Inc revenue
- Grail, Inc. revenue
- Schrodinger, Inc. revenue
Head to head: CTKB vs MRVICTKB vs CYRXCTKB vs MLAB
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies